Clinical Trial Update: Study to Assess the Antiviral Activity and Safety Endpoints for the Treatment of Besifovir 150mg Compared to Tenofovir 300mg in Chronic Hepatitis B Patients Who Have Resistance to Nucleoside Analogues [Phase 3]

View source ↗

Summary

Phase 3 trial comparing besifovir 150mg to tenofovir 300mg in chronic hepatitis B patients with nucleoside analogue resistance has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis B

Drugs mentioned

• Besifovir (besifovir)
• Tenofovir (Tenofovir)

Snippet

Sponsor: IlDong Pharmaceutical Co Ltd | Conditions: Chronic Hepatitis B | Phase 3 | Status: COMPLETED